BOTHELL - Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine .
The combination showed.
Seagen (SGEN) to Present New Data for ADCETRIS with Immunotherapy Combination in Hodgkin Lymphoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session –– First preclinical data for investigational antibody-drug conjugate SGN-35C to be presented –BOTHELL, Wash. (BUSINESS WIRE) #ASH23 Seagen Inc. (NASDAQ: SGEN) t.
Seagen Inc.: TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.